左旋多巴和脱羧酶抑制剂诱发的痛风。
Gout induced by L-dopa and decarboxylase inhibitors.
作者信息
Calne D B, Fermaglich J
出版信息
Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.
Abstract
Two cases of clinical gout are reported in parkinsonian patients receiving L-dopa in combination with a decarboxylase inhibitor. Blockade of decarboxylation leads to major changes in the pattern of L-dopa metabolites. It is suggested that hyperuricaemia may result from accumulation of L-dopa itself or a transaminated product.
摘要
报告了两例接受左旋多巴联合脱羧酶抑制剂治疗的帕金森病患者出现临床痛风的病例。脱羧作用的阻断导致左旋多巴代谢产物模式发生重大变化。有人认为高尿酸血症可能是由左旋多巴本身或一种转氨产物的积累所致。
相似文献
1
Gout induced by L-dopa and decarboxylase inhibitors.
Postgrad Med J. 1976 Apr;52(606):232-3. doi: 10.1136/pgmj.52.606.232.
2
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001.
3
[CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
Acta Neurol (Napoli). 1976 Jul-Aug;31(4):479-48.
4
[Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
Neurol Neurochir Pol. 1977 Jan-Feb;11(1):73-80.
5
[Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
Cesk Neurol Neurochir. 1975 Dec;38(6):327-32.
6
Treating parkinsonism with L-dopa and carboxylase inhibitor.
Mod Med Asia. 1977 Sep;13(9):23-5.
7
Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
Med Ann Dist Columbia. 1974 Dec;43(12):587-91.
8
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Acta Neurol Scand. 1977 Dec;56(6):508-24. doi: 10.1111/j.1600-0404.1977.tb01456.x.
9
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Arch Neurol. 1977 Apr;34(4):228-32. doi: 10.1001/archneur.1977.00500160042007.
10
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Neurol Neurocir Psiquiatr. 1976;17(4):293-300.
引用本文的文献
1
Association of polymorphisms in genes involved in the dopaminergic pathway with blood pressure and uric acid levels in Chinese females.
J Neural Transm (Vienna). 2010 Dec;117(12):1371-6. doi: 10.1007/s00702-010-0492-6. Epub 2010 Oct 8.
本文引用的文献
1
[Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
Presse Med (1893). 1971 Jan 16;79(3):91-2.
2
False rise in serum uric acid after L-dopa.
N Engl J Med. 1969 Dec 25;281(26):1489-90.
3
Gout while receiving levodopa for Parkinsonism.
JAMA. 1972 Jan;219(1):55-7.
4
Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
Mayo Clin Proc. 1972 Jun;47(6):389-95.
5
Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
Nature. 1974 Feb 8;247(5440):364-6. doi: 10.1038/247364b0.
6
Parkinsonism treated with 3-O-methyldopa.
Clin Pharmacol Ther. 1973 May-Jun;14(3):386-9. doi: 10.1002/cpt1973143386.
7
Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
J Neurol Sci. 1972 Sep;17(1):45-51. doi: 10.1016/0022-510x(72)90021-4.
Zotero 插件